Variation in Ophthalmologist Use of Antivascular Endothelial Growth Factor Therapy Among Medicare Beneficiaries

JAMA Ophthalmol. 2016 Sep 1;134(9):1071-2. doi: 10.1001/jamaophthalmol.2016.2051.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Bevacizumab / therapeutic use
  • Drug Utilization / statistics & numerical data*
  • Humans
  • Intravitreal Injections
  • Medicare Part B / statistics & numerical data*
  • Ophthalmologists / statistics & numerical data*
  • Practice Patterns, Physicians' / statistics & numerical data*
  • Ranibizumab / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • United States
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Bevacizumab
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab